Suven Life Sciences

Cohance Lifesciences shares fell over 10% to a 52-week low after MD V Prasada Raju resigned. The pharma firm also faces USFDA "Official Action Indicated" status for its Hyderabad facility

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details

Shares of Suven Life Sciences and Camlin Fine Sciences hit their respective life-time highs, surging up to 9 per cent on the BSE in Monday's intra-day trade.

Technical outlook on smallcap stocks - Anand Rathi, Suven Life Sciences, Pfizer, Clean Science and Jindal Saw seem to be favourably placed, and can potentially gain up to 19% from here on.

Suven Life Sciences hit a record high of ₹175, surging 15 per cent today, as the Board approved a fundraising plan of ₹857.64 crore

Merger-bound Suven Pharmaceuticals and Cohance Lifesciences aim to more than double their combined revenue to around Rs 6,000 crore by FY29 by undertaking both organic and inorganic growth routes, a top company official said. The entities reported a combined revenue of Rs 2,392 crore in FY24. The merged entity aims to put in place an aggressive plan to more than double revenue to Rs 6,000 crore by FY29 through both organic and inorganic growth routes, Suven Pharma Managing Director Prasada Raju said. The merger between Suven and Cohance has received approval from both NSE & BSE. As directed by National Company Law Tribunal (NCLT), the shareholders meeting of both Suven Pharmaceuticals and Cohance Lifesciences amalgamation will be held on November 28, 2024. Once finalised and approved, the combined entity will focus on three core growth drivers: pharma CDMO, specialty chemicals CDMO, and active pharmaceutical ingredients (APIs). "Together, we're building a powerhouse poised to ...

The study aimed to evaluate the safety and tolerability of Ropanicant in patients with Major Depressive Disorder

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

The newly formed company is said to focus on three main verticals - Pharma CDMO, Agrochemicals CDMO, and API manufacturing

Shares of Wockhardt hit a multi-year high of Rs 943.20, zooming 65 per cent in past nine trading days.

Technical charts suggest that Suven Pharma may trade with a positive bias in the near-term, provided the stock manages to hold above these key support levels.

PRESCRIPTION FOR CAUTION: Analysts sound alarm on valuations after past year's recovery

The Competition Commission of India (CCI) on Thursday said it has cleared Berhyanda Ltd's acquisition of a 76.10 per cent stake in pharmaceutical firm Suven Pharmaceuticals Ltd. Berhyanda Ltd is a wholly-owned subsidiary of Berhyanda Midco Ltd, which is an affiliate of Advent International Corporation. The proposed combination relates to the acquisition by Berhyanda Ltd for up to 76.10 per cent of the voting share capital of Suven Pharmaceuticals Ltd, by way of a share purchase agreement dated December 26, 2022, and pursuant to the mandatory open offer in compliance with Sebi's SAST (Substantial Acquisition of Shares and Takeovers) regulations, according to an official release. Suven Pharmaceuticals Ltd is a biopharmaceutical company that offers its services to global pharmaceutical and agrochemical majors. Deals beyond a certain threshold require approval from the regulator, which keeps a tab on unfair business practices in the marketplace.

'Suven alone has multiple engines of growth across all segments and a strong pipeline of Phase 3 and late Phase 2 molecules'

CLOSING BELL: The S&P BSE Sensex ended with a marginal loss of 88 points, while the Nifty held the 18,300-level on Friday.

Stocks to watch today: Tata Motors bagged order for 1,000 buses from Haryana Roadways; ABFRL inked pact with Galeries Lafayette to open luxury department stores in India

Clinical trial randomisation is the process of assigning patients by chance to groups that receive different treatments

The stock had hit a 52-week low of Rs 62 on June 20, 2022, and has corrected 50 per cent from its record high level of Rs 124 touched on October 8, 2021

Stocks to Watch Today: Indiabulls Housing Finance and RBL Bank are the two stocks in F&O ban period on Tuesday.

Markets regulator Sebi on Thursday disposed of proceedings against Suven Life Sciences Ltd, Jasti Family Trust and four other individuals, including the firm's chairman and CEO Venkateshwarlu Jasti